UPSTREAM BIO, INC. Share-based Payment Arrangement, Expense
UPSTREAM BIO, INC. (UPB) reported Share-based Payment Arrangement, Expense of $4.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- UPSTREAM BIO, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.35M, a 67.65% increase year-over-year.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $4.65M, a 76.36% increase year-over-year.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.51M, a 20.13% increase year-over-year.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.59M, a 39.24% increase year-over-year.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for fiscal 2025 was $10.33M, a 72.09% increase from fiscal 2024.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for fiscal 2024 was $6.00M, a 75.20% increase from fiscal 2023.
- UPSTREAM BIO, INC. share-based payment arrangement, expense for fiscal 2023 was $3.43M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.35M 10-Q · filed 2026-08-11 | $9.00M 10-Q · filed 2026-08-11 | $11.51M derived: sum of 3 quarters · filed 2026-08-11 | $14.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.65M 10-Q · filed 2026-05-13 | $7.15M derived: sum of 2 quarters · filed 2026-05-13 | $9.75M derived: sum of 3 quarters · filed 2026-05-13 | $12.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.10M derived: sum of 2 quarters · filed 2026-03-26 | $7.70M derived: sum of 3 quarters · filed 2026-08-11 | $10.33M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-05 | $5.19M derived: sum of 2 quarters · filed 2026-08-11 | $7.83M 10-Q · filed 2025-11-05 | $9.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.60M 10-Q · filed 2026-08-11 | $5.23M 10-Q · filed 2026-08-11 | $7.32M derived: sum of 3 quarters · filed 2026-08-11 | $9.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.63M 10-Q · filed 2026-05-13 | $4.72M derived: sum of 2 quarters · filed 2026-05-13 | $6.58M derived: sum of 3 quarters · filed 2026-05-13 | $8.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.95M derived: sum of 2 quarters · filed 2026-03-26 | $5.36M derived: sum of 3 quarters · filed 2026-03-26 | $6.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.86M 10-Q · filed 2025-11-05 | $3.27M derived: sum of 2 quarters · filed 2025-11-05 | $3.92M 10-Q · filed 2025-11-05 | $4.73M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.41M 10-Q · filed 2025-08-06 | $2.06M 10-Q · filed 2025-08-06 | $2.87M derived: sum of 3 quarters · filed 2025-08-06 | $3.55M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $643.00K 10-Q · filed 2025-05-06 | $1.46M derived: sum of 2 quarters · filed 2025-05-06 | $2.14M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.50M derived: sum of 2 quarters · filed 2025-03-12 | $3.43M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $683.00K 10-Q · filed 2024-11-07 | $2.61M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |